Federated Hermes Inc. boosted its holdings in shares of Rezolute, Inc. (NASDAQ:RZLT – Free Report) by 11.1% during the 2nd quarter, Holdings Channel.com reports. The firm owned 11,279,327 shares of the company’s stock after purchasing an additional 1,125,000 shares during the quarter. Federated Hermes Inc. owned approximately 0.28% of Rezolute worth $48,501,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in the business. Jeppson Wealth Management LLC bought a new position in Rezolute during the second quarter worth $45,000. Virtu Financial LLC acquired a new stake in shares of Rezolute during the first quarter worth $37,000. Rosalind Advisors Inc. lifted its position in shares of Rezolute by 25.0% in the 2nd quarter. Rosalind Advisors Inc. now owns 250,000 shares of the company’s stock worth $1,075,000 after buying an additional 50,000 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Rezolute in the 1st quarter valued at about $229,000. Finally, Vanguard Group Inc. grew its position in shares of Rezolute by 10.4% during the 1st quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company’s stock valued at $3,961,000 after buying an additional 145,700 shares during the last quarter. 82.97% of the stock is owned by institutional investors and hedge funds.
Rezolute Stock Performance
Shares of NASDAQ:RZLT opened at $5.25 on Friday. The firm has a 50 day simple moving average of $4.55 and a 200 day simple moving average of $3.62. Rezolute, Inc. has a 52 week low of $0.72 and a 52 week high of $6.10. The company has a market cap of $210.71 million, a PE ratio of -4.61 and a beta of 1.18.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on RZLT
Rezolute Profile
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Featured Stories
- Five stocks we like better than Rezolute
- How to Plot Fibonacci Price Inflection Levels
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- What Are Dividend Champions? How to Invest in the Champions
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- Trading Halts Explained
- MarketBeat Week in Review – 9/9 – 9/13
Want to see what other hedge funds are holding RZLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rezolute, Inc. (NASDAQ:RZLT – Free Report).
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.